Presentatie van Bert Reijmerink (Genalice) - 'Hoe technologie bijdraagt aan een betere behandeling van kankerpatiënten' tijdens het Big Data Analytics seminar 14 juni in Almere

1. Hoe technologie bijdraagt aan een
betere behandeling van
kankerpatiënten
Bert Reijmerink
Chief Executive Officer
Confidential 1

2. THE FIRST AND FASTESTS
OPEN BIG MEDICAL DATA ANALYSIS PLATFORM
INTEGRATING & CORRELATION BIOMEDICAL DATA
2 Copyright © 2012 Genalice B.V.

3. OUR DREAM
TO SAVE LIVES
AND IMPROVE
QUALITY OF LIFE
OF CANCER PATIENTS
3

4. DNA technology is moving at high pace
Medical data is produced with high speed
13 Years 2 months 8 days <1 hour
$3,000,000,000 $2,000,000 $10,000 $1,000
2003 2007 2012

5. BUT… data ≠ knowledge & insights
As is needed to improve patient care
TTTATCGGAATCCGATTTCGAAACTGGGTATATCCCGGGGAAATCTCGTATAG
CTCTCGAGCTCTCGCAAAATTTTTCTCCGCGCGCTTTGATGCATCGGCTACGA
TCGTAGCTACGACGATGCTACGCTAGTGGGGGTATTTCTATCACACACAAACA
CGATCGTAGCTGTTTTTTCCCCCGGGTGTGTACGATCAAACGACTGACTACGA
TCGATCGATCGATCAGCTAGCTACGACTGACTAGCTGACTAGCTAGCTAGCTA
GCTAGCTACGTAGCTACGATCGATCGATCGATCGATCGATCGATCGACGGATG
TGGTGTGTTTCTTTTTCTTCAAAAAACCAACACATCGATCGACTGTACGATCG
ATGCTACGTAGCATCGATCGATCACGTCAGATCGATGCTACGATCGCGATCGG
ATCGATCGATCGATGATCGATCATTTCGCGTCCATTTTCCGCTTCGGGATTTGA
TGATCGCGGTTTTATAGCTAGTTA……. 3 billion in total = 25 TB
5

6. At the brink of BIG changes
Enabled through advances in DNA production and by powerful data analysis
Confidential 6

7. High-Throughput Sequencing goes global
Approximate number of machines (by country)
Confidential 7

8. DNA data production is Skyrocketing
Number of sequenced full human genomes
Confidential 8

9. Big change – Big opportunity
According to McKinsey
U.S. healthcare sector could create
more than $300 billion in value
every year if it were to “use big
data” creatively and effectively to
drive efficiency and quality
McKinsey, 2011

10. The medical BIG DATA challenge
Up to 45 TB of diagnostic data per patient from different sources
Gene
Expression DNA
variations
Proteomics
Clinical Data
Pathology
Imaging Any other
dataset
Confidential 10

11. Research is still moving a slow pace
Key issues that slow down clinical applications
Non-integrated Selective Separate
Confidential 11

12. Technology is the solution
To boost research and improved patient treatment
Integrated data processing & analysis software:
Master the size
Master the format
Master the compute
Facilitate cooperation
Confidential 12

13. Reducing the size of DNA data
Enables high volume analyses
Full genome sequence: Alignment output file: Genalice format:
± 25 Terabytes ± 1.2 Terabytes ± 200 Megabytes
DNA data production Preprocessing Downstream analysis
Confidential 13

14. Transform and uniform data
Allows for diagnostic multi-domain integration
DNA
variations
Gene
Expression
Proteomics
Imaging
INTEGRATION
Clinical Data
Pharmaco-
genomics
Pathology
14

15. Integration of existing knowledge
o
Provides a 360 view of a patient’s specific disease and boosts research
DNA
variations
Gene
Expression
Proteomics
Imaging
INTEGRATION
Clinical Data
Pharmaco-
genomics
Pathology
15

16. Unraveling multi-domain correlations
Will boost discovery towards 1st time right treatment
DNA
variations
Gene
Expression
Proteomics
INTEGRATION
Imaging Cancer
Treatment
Clinical Data
Pharmaco-
genomics
Pathology
16

17. Micro parallel processing
Warrants high performance analysis
Weeks
Time to result
Seconds
Confidential 17

18. Micro parallel processing
Warrants high performance analysis
Number of patients in one run
100K-1M
10-50
Confidential 18

19. Facilitating high volume data sharing
A power multiplier for biomarker discovery projects
19

20. Biomarkers: from research to clinic
High volume data internally validates digitally stored biomarkers
DNA
variations
Gene
Expression
Proteomics
INTEGRATION
Imaging RESEARCH Biomarker
Biomarker Check
Find Clinic
Clinical Data
validation
value value
Any other
dataset
Pathology
20

21. Game changing technology and approach
Containing six patentable new techniques
Uniform Format Data Selection Data Movement
Causality/Correlation Pattern Index NB micro Scheduler
Confidential 21

22. Our technology facilitates
Faster Diagnosis (within 24 hrs)
Reliability
Targeted Treatment (1st time right)
Joint Effort
Efficiency
Time/Resources gains in Research
Cost Improved Drug Development
Confidential 22

23. Why is Genalice worth working with?
Market at the brink to explode
Best positioned company to capture major share
Groundbreaking technology and approach
Excellent team and network
Potential use in other diseases & markets
Confidential 23

24. Potential use in other diseases and markets
As our software is a generic BIG DATA cruncher
1. Oncology market (largest medical segment)
2. Application for other diseases McKinsey BIG DATA Report 2011
3. Other applications
(outside the medical field)
Confidential 24

25. Partners & launching customers
University hospital
Maastricht
Amsterdam
Confidential 25

26. Excellent team and network
The Jockeys
Bert Reijmerink Hans Karten Jos Lunenberg
Chief Executive Officer Chief Technology Officer Chief Business Officer
Senior Business Developer IT Senior Development Oracle Master Degree Molecular
11 patents Biology & MBA
International Marketing
Health/Life Science
Confidential 26

27. Excellent team and network
Our scientific advisory board
Amsterdam
Prof. Gerrit Meijer Prof. Edwin Cuppen
VUMC Amsterdam UMC Utrecht
PrincipaI Investigator TraIT (CTMM) Head of Research Medical Genetics
Confidential 27

28. Excellent team and network
Our first board member
RONALD BRUS, MD
Former positions:
CEO of Crucell (sold to J&J for 2.4B)
Board member Galapagos (listed AMEX)
Confidential 28

29. Genalice supports Alpe d’Huzes
Chirurgen tegen kanker
Confidential 29